Over 40 years of topical GHK-Cu research have established a strong safety profile, but the injectable route has less human data available
Real-life testimonials and clinical studies showcase the profound impact these programs can have on individuals striving for a healthier lifestyle
First, de novo protein design does not rely on animal immunization and yields proteins that can be manufactured using recombinant DNA technology, thereby creating a source for the continuous production of products with limited batch-to-batch variation
People who tolerate the 8mg dose well and want to maximize efficacy should advance to 12mg
We source our raw peptide from FDA-reviewed, DMF-listed manufacturers, and every batch undergoes testing by two independent third-party laboratoriesEagle Analytical and ARL Labsto ensure purity, potency, and the absence of contaminants
Convenient Weekly Dosing Once-weekly injections improve adherence and give patients a sense of simplicity and freedom (Kommu & Whitfield, 2024)